IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM - PubMed
5 days ago
- #daratumumab
- #multiple myeloma
- #genomic staging
- IMS-IMWG 2025 consensus genomic staging (CGS) defines high-risk (HR) newly diagnosed multiple myeloma (NDMM) patients, including TP53 mutations and IgH translocations with chromosome 1 aberrations.
- The study analyzed 503 NDMM patients treated with daratumumab-based quadruplet therapy, with 31% classified as HR by CGS.
- CGS did not predict early minimal-residual disease (MRD) status but significantly predicted progression-free survival (PFS), with HR patients having a median PFS of 2.6 years vs. not reached in standard risk (SR) patients.
- CGS risk remained predictive of PFS even in MRD-negative patients post-autologous stem cell transplantation.
- The CGS is recommended for standardizing NDMM trial design, but MRD-guided trials should also consider genomic risk.